metastatic pancreatic cancer
Conditions
Brief summary
Quality Adjusted Overall Survival
Detailed description
Time to disease progression after inclusion (Restricted mean progression free survival (RM-PFS): area under the Kaplan-Meier PFS curve between inclusion and maximum follow-up of the study, estimated 12 months), Quality adjusted Progression Free Survival (PFS), Overall survival (in months), Duration of time without symptoms of disease progression or toxicities (TWiST), Adverse events according to NCI CTC version 5.0, Change in CA 19.9
Interventions
DRUGAbraxane 5 mg/ml powder for dispersion for infusion.
DRUGCampto 20 mg/ml
DRUGGemcitabine Accord 100 mg/ml Concentraat voor Oplossing voor Infusie
Sponsors
Amsterdam UMC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality Adjusted Overall Survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to disease progression after inclusion (Restricted mean progression free survival (RM-PFS): area under the Kaplan-Meier PFS curve between inclusion and maximum follow-up of the study, estimated 12 months), Quality adjusted Progression Free Survival (PFS), Overall survival (in months), Duration of time without symptoms of disease progression or toxicities (TWiST), Adverse events according to NCI CTC version 5.0, Change in CA 19.9 | — |
Countries
Netherlands
Outcome results
None listed